聚焦中药创新药，方盛制药又一重磅品种发布

Group 1 - The core viewpoint of the news is the launch of a new traditional Chinese medicine product, "Yangxue Qufeng Zhitong Granules," by Fangsheng Pharmaceutical, which aims to address frequent tension-type headaches and has received regulatory approval [1][3]. - The new drug is based on the classic formula "Shengxian Decoction" by renowned physician Zhang Xichun and has undergone over ten years of research and clinical trials, making it the first innovative traditional Chinese medicine specifically targeting tension-type headaches in China [1][2]. - The development of "Yangxue Qufeng Zhitong Granules" began in 2014 with an investment of approximately 27 million yuan, completing various clinical trials and toxicity studies, demonstrating its efficacy in reducing headache frequency, duration, and intensity [2][3]. Group 2 - Fangsheng Pharmaceutical has established a core competitive advantage in new drug development, focusing on increasing R&D investment to enhance the speed and efficiency of innovative traditional Chinese medicine [3]. - The approval of "Yangxue Qufeng Zhitong Granules" enriches the company's product pipeline and strengthens its competitive position in the market, aligning with its strategy to become a health industry group centered on innovative traditional Chinese medicine [3]. - The product has been included in the national medical insurance catalog, which is expected to enhance its market accessibility and potentially improve the overall profitability of Fangsheng Pharmaceutical [3].